TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05421494

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: minimal contact control
Description: Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: minimal contact control
Description: Participants assigned to MCC will be asked to not work with other therapists or seek additional treatment for trauma-related difficulties during the 3-week MCC period. They will be video-called once per week by a therapist to monitor their status and to provide support as needed. The calls will be limited to 10-15 minutes. MCC participants will also be given contact information to use in case of worsening symptoms or increasing distress.
Study: NCT05654181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: investigational drug administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: investigational drug administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: investigational drug administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching active drug administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching active drug administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching active drug administered orally
Study: NCT05571839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-08046049
Description: Given into the vein (IV; intravenous)
Study: NCT05695300

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BLM ORGANIC GOLD+
Description: Participants in this arm need to be fed the assigned infant formula daily for three months, no other formula or breast milk

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BLM ORGANIC
Description: Participants in this arm need to be fed the assigned infant formula daily for three months,no other formula or breast milk
Study: NCT05543174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-625
Description: TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily
Study: NCT05695300

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Breast milk
Description: Participants in this arm need to be fed with breast milk daily for three months, no infant formula
Study: NCT06581120

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care Gastric Ultrasound
Description: A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.

Intervention type: DIAGNOSTIC_TEST
Intervention: Point of Care Gastric Ultrasound
Description: A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.
Study: NCT05301816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (SCS)
Description: Spinal cord stimulation system (SCS) is an approved system to manage chronic intractable pain of the limbs and/or leg by delivering electrical stimulation using implantable leads and rechargeable implantable pulse generator (IPG) with 16 output channels. The IPG is implanted in a subcutaneous pocket and is capable of stimulating the spinal cord nerves when used with one or two 8-contact percutaneous or paddle leads.
Study: NCT04643002

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pharmaceutical form: Capsule; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegenzileukin
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Description: Pharmaceutical form: tablet; route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evorpacept
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Study: NCT06052813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104
Description: Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104
Description: Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104
Description: Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104
Description: Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN104
Description: Will be administered orally once daily (approximately every 24 hours) for the first cohort or twice daily (approximately every 12 hours) for the subsequent cohorts.
Study: NCT05767762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scale Idiopathic Clubfoot
Description: The Dimeglo and the muscle activity scale will be performed at 3, 6 and 12 months with patient with idiopathic clubfoot
Study: NCT05110898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg
Description: Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)
Description: Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.
Study: NCT04910347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dosage within 12 weeks after the end of concurrent chemoradiation therapy. Nivolumab 360mg Intravenously administered every 3 weeks.~As a consolidation regimen, administration of Nivolumab is administered for up to a total of 1 year until disease progression or unacceptable to toxicity occurs.
Study: NCT04717882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDSS-OPTIMED
Description: The CDSS-OPTIMED is a software program that provides the physician with a personalized alert on whether to consider stopping or starting medication for a specific patient.
Study: NCT05824949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseodensification drilling
Description: Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the osseodensification protocol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional drilling
Description: Implant mechanical and biological stability measured using ISQ values at the time of implant placement and at abutment connection for 40 implants placed in the posterior maxillary area using the conventional drilling protocol.
Study: NCT06633549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Accidents Prevention Training
Description: Mothers in the education group who participated in the study were informed about the research and their written consent was obtained. Mothers filled out the 'Information Form' then completed the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6 Years'. Mothers were helped when filling out the form and their questions were answered. The training program was organized so that there would be a maximum of 5 mothers in each group. The trainings were conducted face-to-face with a PowerPoint presentation and lasted about 40-45 minutes. Question-answer and discussion methods were used during the training. After the training, the mothers were asked to fill out the same scale again one month later. One month after the training, the mothers were interviewed face-to-face and the scale was filled in again and the changes they made at home were recorded.
Study: NCT06317376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MICT with Aerobic exercise on treadmill
Description: MICT 3 session per week with Aerobic exercise on treadmill for 30 minute with moderate intensity.
Study: NCT06417437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Description: Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
Study: NCT06633549

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Mothers in the control group were informed about the research and the 'Informed Consent Form' was signed. The mothers filled out the 'Information Form' and this process took about 15-20 minutes. Mothers were helped when filling out the form and their questions were answered. In addition, mothers were asked to complete the 'Diagnostic Scale of the Mother's Safety Measures for Home Accidents in Children Aged 0-6' by introducing. A month later, they were informed that they had to fill out this scale again. A month later, the mothers were interviewed face-to-face and allowed to fill out the scale again. After the last test, the mothers in the control group were given 'Home Accidents and Prevention Training for Children in the 0-6 Age Group' and the output of the training presentation was distributed.
Study: NCT06317376

Intervention type: OTHER
Group type: OTHER
Intervention: standard hospital protocol
Description: standard hospital protocol
Study: NCT06134908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted Intervention
Description: The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.
Study: NCT06199050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: SPIRIT
Description: T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: SPIRIT
Description: T0: Before the first intake at Maastro, the Trialpoli (TP) contacts a patient via phone to inform whether or not he is interested in participating in this study. If the patient shows interest in participating in the study, he will be invited for a consultation with the Trialpoli. This consultation takes place on the day of intake at Maastro. After consent, the patient is randomized to fill out T0 before or after the intake.~T1: After filling out T0, the patient receives the ENGAGE information card with the url en QR code to the VR-movie. After watching the VR movie and before start RT the patient is asked to fill in T1. This questionnaire is distributed with instructions by the TP.~T2: Between the 5th and the 15th radiation treatment, patients will be asked to fill in the questionnaires for the third and last time. The Patient Information Form (PIF) and Informed Consent (IC) are added in a separate document.
Study: NCT06410508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Just Do You
Description: As described in further detail previously, the experimental intervention is a brief psychotherapeutic intervention informed by principles of CBT and motivational interviewing that is co-delivered by a mental health clinician and peer support worker. This intervention will be a version of the initial intervention delivered in the Just Do You trial by Munson et al.(2022), adapted for increased suitability with our clinical population.
Study: NCT06199050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: HADS
Description: Hospital Anxiety and Depression Scale, 14 questions likert scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: HADS
Description: Hospital Anxiety and Depression Scale, 14 questions likert scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: QSC-R23
Description: Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire: QSC-R23
Description: Dutch version of the Questionnaire on stress symptoms, 23 questions likert scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General questions
Description: * Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General questions
Description: * Education level~* Marietal status~* Medication use (in order to assess influence on fear)~* Previous cancer diagnosis~* Acquired information on treatment~* Expected fear and anxiety mitigation strategies~* Other cancer treatments (e.g. chemotherapy no, prior to RT, during RT, or after RT; surgery prior to or after RT)~* PROM at baseline
Study: NCT06417437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.
Study: NCT06199050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical data collected
Description: Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical data collected
Description: Clinical data in HIX:~* Age~* Gender~* Cancer type~* WHO status~* TNM
Study: NCT06417437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Patients are not masked from the types of intervention they receive. Assessment will be done before and after each intervention. Each group is independent from other groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Patients will be treated targeting either the traditional brain region or new region.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Patients will be treated targeting either the traditional brain region or new region.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-Feedback
Description: Patients under 18 years old will first be considered this treatment before other methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Regulation
Description: Patients will learn how to play several games that can supposedly regulate or affect negative emotions.
Study: NCT04726852

Intervention type: DEVICE
Intervention: Concurrent comparison
Description: Concurrent comparisons at defined procedure events
Study: NCT06058403

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 20g whey protein drink ingestion
Description: Ingestion of a 300 mL drink containing 20g whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20g native canola protein drink ingestion
Description: Ingestion of a 300 mL drink containing 20g native canola protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20g processed canola protein #1 drink ingestion
Description: Ingestion of a 300 mL drink containing 20g processed canola protein #1
Study: NCT04850287

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Digital Sensors for Population Awareness about Health Issues using Social Media
Description: A clustered randomized control trial will be conducted and ZIP Codes from each demographic environment will be randomly assigned to control and intervention arms. Digital educational materials about organ donation will be exposed to online users in social media belonging to ZIP Codes assigned to the intervention arm
Study: NCT06055621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Daily orally administration of DASATINIB
Study: NCT04580407

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-672
Description: B-Domain Deleted Recombinant Porcine Factor VIII
Study: NCT05473520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: A dose of 100 mg twice daily of doxycycline based on the recommended dose for adults which is commonly used for bacterial infections such as rickettsial infection, lyme disease and pelvic inflammatory disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + standard anti-tuberculous treatment
Study: NCT06522035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra
Description: Intra-articular injecton of Allocetra into the target joint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra
Description: Intra-articular injecton of Allocetra into the target joint.
Study: NCT06058403

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20g processed canola protein #2 drink ingestion
Description: Ingestion of a 300 mL drink containing 20g processed canola protein #2
Study: NCT06652763

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: Full blood count, Urea and electrolytes, Liver function tests, Glucose and HbA1c, Insulin and C-peptide, NTproBNP, High sensitive troponin I, storage of plasma for future analyses
Study: NCT05273801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Rate Recording from Multiple Participants, No Visual Feedback
Description: Heart rates are recorded from multiple participants during the group sessions. However during this intervention, it will not be cast to a TV for feedback to the participant or clinician.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual Feedback of Multiple Participant Heart Rates
Description: Visual feedback of HR is provided through a TV monitor. Multiple heart rates can be displayed and recorded simultaneously allowing for group encouragement, continuous monitoring and adjustment of all participants to ensure reaching appropriate target intensity.